{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:08:00Z","timestamp":1790957280704,"version":"4.1.0"},"reference-count":61,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the impact of GLP-1 receptor agonists (GLP-1 RAs) on metabolic inflammatory markers in patients with type 2 diabetes mellitus (T2DM), providing evidence-based insights for their potential application in anti-inflammatory therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Research questions were developed using the PICOS framework, and the study strictly adhered to PRISMA guidelines. Comprehensive literature searches were conducted across PubMed, EBSCO, Embase, Web of Science, and the Cochrane Library. Data synthesis and subgroup analyses (focusing on GLP-1 RA subtypes, treatment duration, and administration frequency) were performed using RevMan 5.4 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 1,347 articles retrieved, 25 studies were ultimately included, comprising a total sample of 1,878 participants (879 in the experimental groups and 999 in the control groups). Quality assessment indicated that most studies exhibited a low risk of bias, with only one study rated as high risk and three studies showing some concerns. Meta-analysis results demonstrated that 18 studies reported a significant reduction in CRP levels in T2DM patients treated with GLP-1 RAs (SMD = \u22120.39, 95% CI [\u22120.72 to \u22120.06],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.02, I\n                      <jats:sup>2<\/jats:sup>\n                      = 88%). Although the results from 13 studies indicated a decreasing trend in IL-6 levels (SMD = \u22120.52), this change was not statistically significant (95% CI [\u22121.34 to 0.29],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.21, I\n                      <jats:sup>2<\/jats:sup>\n                      = 96%). Additionally, 14 studies showed that GLP-1 RAs significantly reduced TNF-\n                      <jats:italic>\u03b1<\/jats:italic>\n                      levels (SMD = \u22120.51, 95% CI [\u22120.81 to \u22120.20],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.001, I\n                      <jats:sup>2<\/jats:sup>\n                      = 81%). Subgroup analyses revealed that both the type of GLP-1 RA and a longer treatment duration (\u226536 weeks) were associated with more pronounced improvements in inflammatory markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      GLP-1 RAs exhibit a certain degree of anti-inflammatory effect in patients with T2DM, effectively reducing CRP and TNF-\n                      <jats:italic>\u03b1<\/jats:italic>\n                      levels. The anti-inflammatory efficacy appears to be influenced by both the type of drug used and the duration of treatment, with more pronounced effects observed for specific drug classes and with longer treatment periods. These findings provide further evidence supporting the use of GLP-1 RAs in the anti-inflammatory management of T2DM.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20710","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:38:52Z","timestamp":1770107932000},"page":"e20710","source":"Crossref","is-referenced-by-count":6,"title":["The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.7717","volume":"14","author":[{"given":"Fang","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Sports Teaching and Research, Lanzhou University, Lanzhou, GanSu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoshu","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Physical Education, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenguang","family":"Li","sequence":"additional","affiliation":[{"name":"School of Physical Education, Huzhou University, Huzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezhang","family":"Yun","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao, China"},{"name":"School of Physical Education, Zhejiang Guangsha Vocational and Technical University of Construction,  Dongyang, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Sports Teaching and Research, Lanzhou University, Lanzhou, GanSu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"10.7717\/peerj.20710\/ref-1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/dom.14343","article-title":"Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: analyses from the LYDIA trial","volume":"23","author":"Ahmad","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.7717\/peerj.20710\/ref-2","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.metabol.2013.07.001","article-title":"Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance","volume":"62","author":"Aroor","year":"2013","journal-title":"Metabolism"},{"key":"10.7717\/peerj.20710\/ref-3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4149\/gpb_2021005","article-title":"Hepatoprotective effect of gallic acid against type 2-induced diabetic liver injury in male rats through modulation of fetuin-A and GLP-1 with involvement of ERK1\/2\/NF-\u03baB and Wnt1\/\u03b2-catenin signaling pathways","volume":"40","author":"Bashar","year":"2021","journal-title":"General Physiology and Biophysics"},{"key":"10.7717\/peerj.20710\/ref-4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s10787-023-01239-4","article-title":"Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.7717\/peerj.20710\/ref-5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.7717\/peerj.20710\/ref-6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","article-title":"Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial","volume":"64","author":"Bouchi","year":"2017","journal-title":"Endocrine Journal"},{"key":"10.7717\/peerj.20710\/ref-7","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"10.7717\/peerj.20710\/ref-8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/jcma.0000000000000844","article-title":"Glucagon-like peptide-1 receptor regulates receptor of advanced glycation end products in high glucose-treated rat mesangial cells","volume":"86","author":"Chang","year":"2023","journal-title":"Journal of the Chinese Medical Association"},{"key":"10.7717\/peerj.20710\/ref-9","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41401-021-00836-9","article-title":"GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis","volume":"43","author":"Chen","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.7717\/peerj.20710\/ref-10","doi-asserted-by":"publisher","first-page":"9351","DOI":"10.3390\/ijms25179351","article-title":"Mechanistic pathways and clinical implications of GLP-1 receptor agonists in type 1 diabetes management","volume":"25","author":"Delrue","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"10.7717\/peerj.20710\/ref-11","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/j.1464-5491.2012.03699.x","article-title":"Exenatide plus metformin compared with metformin alone on \u03b2-cell function in patients with Type 2 diabetes","volume":"29","author":"Derosa","year":"2012","journal-title":"Diabetic Medicine"},{"key":"10.7717\/peerj.20710\/ref-12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/dia.2009.0141","article-title":"Exenatide versus glibenclamide in patients with diabetes","volume":"12","author":"Derosa","year":"2010","journal-title":"Diabetes Technology & Therapeutics"},{"key":"10.7717\/peerj.20710\/ref-13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejphar.2011.05.051","article-title":"Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients","volume":"666","author":"Derosa","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"10.7717\/peerj.20710\/ref-14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.diabres.2014.01.019","article-title":"Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study","volume":"104","author":"D\u00edaz-Soto","year":"2014","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.7717\/peerj.20710\/ref-15","doi-asserted-by":"publisher","first-page":"9853","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.7717\/peerj.20710\/ref-16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nature Reviews Immunology"},{"key":"10.7717\/peerj.20710\/ref-17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/s1734-1140(13)71069-7","article-title":"Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells","volume":"65","author":"Dorecka","year":"2013","journal-title":"Pharmacological Reports"},{"key":"10.7717\/peerj.20710\/ref-18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabolism"},{"key":"10.7717\/peerj.20710\/ref-19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","article-title":"Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes","volume":"105","author":"Esser","year":"2014","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.7717\/peerj.20710\/ref-20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1464-5491.2012.03589.x","article-title":"Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function","volume":"29","author":"Forst","year":"2012","journal-title":"Diabetic Medicine"},{"key":"10.7717\/peerj.20710\/ref-21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.diabres.2014.09.046","article-title":"Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers","volume":"106","author":"Gurkan","year":"2014","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.7717\/peerj.20710\/ref-22","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.5","author":"Higgins","year":"2024"},{"key":"10.7717\/peerj.20710\/ref-23","doi-asserted-by":"publisher","first-page":"790405","DOI":"10.3389\/fendo.2021.790405","article-title":"Effect of 26 weeks of liraglutide treatment on coronary artery inflammation in Type 2 diabetes quantified by [(64)Cu]Cu-DOTATATE PET\/CT: tesults from the LIRAFLAME trial","volume":"12","author":"Jensen","year":"2021","journal-title":"Frontiers in Endocrinology"},{"key":"10.7717\/peerj.20710\/ref-24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1210\/endrev\/bnab021","article-title":"The \u03b2 cell in diabetes: integrating biomarkers with functional measures","volume":"42","author":"Kahn","year":"2021","journal-title":"Endocrine Reviews"},{"key":"10.7717\/peerj.20710\/ref-25","doi-asserted-by":"publisher","first-page":"6423987","DOI":"10.1155\/2019\/6423987","article-title":"A randomized study to compare the effects of once-weekly dulaglutide injection and once-daily glimepiride on glucose fluctuation of type 2 diabetes mellitus patients: a 26-week follow-up","volume":"2019","author":"Li","year":"2019","journal-title":"Journal of Diabetes Research"},{"key":"10.7717\/peerj.20710\/ref-26","doi-asserted-by":"publisher","first-page":"16968","DOI":"10.1038\/srep16968","article-title":"Glucose variability and \u03b2- cell response by GLP-1 analogue added-on CSII for patients with poorly controlled Type 2 diabetes","volume":"5","author":"Lin","year":"2015","journal-title":"Scientific Reports"},{"key":"10.7717\/peerj.20710\/ref-27","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"Journal of Dermatological Treatment"},{"key":"10.7717\/peerj.20710\/ref-28","doi-asserted-by":"publisher","first-page":"110688","DOI":"10.1016\/j.diabres.2023.110688","article-title":"Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes","volume":"200","author":"Longo","year":"2023","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.7717\/peerj.20710\/ref-29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11892-013-0375-y","article-title":"Diabetes mellitus and inflammation","volume":"13","author":"Lontchi-Yimagou","year":"2013","journal-title":"Current Diabetes Reports"},{"key":"10.7717\/peerj.20710\/ref-30","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biology"},{"key":"10.7717\/peerj.20710\/ref-31","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1172\/jci92172","article-title":"Glucose-induced \u03b2 cell production of IL-1\u03b2 contributes to glucotoxicity in human pancreatic islets","volume":"127","author":"Maedler","year":"2017","journal-title":"Journal of Clinical Investigation"},{"key":"10.7717\/peerj.20710\/ref-32","doi-asserted-by":"publisher","first-page":"81ps17","DOI":"10.1126\/scitranslmed.3001902","article-title":"The inflammasome in atherosclerosis and type 2 diabetes","volume":"3","author":"Masters","year":"2011","journal-title":"Science Translational Medicine"},{"key":"10.7717\/peerj.20710\/ref-33","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jdiacomp.2016.05.022","article-title":"Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Mazidi","year":"2017","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.7717\/peerj.20710\/ref-34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","article-title":"Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity","volume":"68","author":"Meier","year":"2025","journal-title":"Diabetologia"},{"key":"10.7717\/peerj.20710\/ref-35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ajpath.2012.09.016","article-title":"Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression","volume":"182","author":"Ojima","year":"2013","journal-title":"The American Journal of Pathology"},{"key":"10.7717\/peerj.20710\/ref-36","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.7717\/peerj.20710\/ref-37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1042\/CS20160803","article-title":"GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction","volume":"131","author":"Pastel","year":"2017","journal-title":"Clinical Science"},{"key":"10.7717\/peerj.20710\/ref-38","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3892\/etm.2017.4863","article-title":"A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus","volume":"14","author":"Quan","year":"2017","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.7717\/peerj.20710\/ref-39","doi-asserted-by":"publisher","first-page":"e012174","DOI":"10.1161\/CIRCIMAGING.120.012174","article-title":"Effect of liraglutide on arterial inflammation assessed as [18F]FDG uptake in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Ripa","year":"2021","journal-title":"Circulation Cardiovascular Imaging"},{"key":"10.7717\/peerj.20710\/ref-40","doi-asserted-by":"publisher","first-page":"571731","DOI":"10.3389\/fimmu.2020.571731","article-title":"Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes","volume":"11","author":"Scheithauer","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20710\/ref-41","article-title":"Effects of GLP-1 receptor agonist on glycolipid metabolism and micro inflammatory status in patients with abdominal obesity and type 2 Diabetes","author":"Shao","year":"2024","journal-title":"Alternative Therapies in Health and Medicine"},{"key":"10.7717\/peerj.20710\/ref-42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.orcp.2017.01.003","article-title":"Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: a randomized controlled trial","volume":"11","author":"Shi","year":"2017","journal-title":"Obesity Research & Clinical Practice"},{"key":"10.7717\/peerj.20710\/ref-43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1159\/000534725","article-title":"Screening for inflammatory markers identifies IL-18R\u03b1 as a potential link between exenatide and its anti-inflammatory effect: new results from the combat-JUDO randomized controlled trial","volume":"79","author":"Stenlid","year":"2023","journal-title":"Annals of Clinical Nutrition and Metabolism"},{"key":"10.7717\/peerj.20710\/ref-44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdi.12269","article-title":"Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: a randomized, parallel-group study","volume":"6","author":"Takeshita","year":"2015","journal-title":"Journal of Diabetes Investigation"},{"key":"10.7717\/peerj.20710\/ref-45","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2337\/dc15-2782","article-title":"Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with Type 2 diabetes at high cardiovascular risk","volume":"39","author":"The FLAT-SUGAR Trial Investigators","year":"2016","journal-title":"Diabetes Care"},{"key":"10.7717\/peerj.20710\/ref-46","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1139\/apnm-2019-0936","article-title":"Receptor for advanced glycation end products modulates oxidative stress and mitochondrial function in the soleus muscle of mice fed a high-fat diet","volume":"45","author":"Velayoudom-Cephise","year":"2020","journal-title":"Applied Physiology, Nutrition, and Metabolism"},{"key":"10.7717\/peerj.20710\/ref-47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Medical Research Methodology"},{"key":"10.7717\/peerj.20710\/ref-48","doi-asserted-by":"publisher","first-page":"2682657","DOI":"10.1155\/2019\/2682657","article-title":"The effects of once-weekly dulaglutide and insulin glargine on glucose fluctuation in poorly oral-antidiabetic controlled patients with Type 2 diabetes mellitus","volume":"2019","author":"Wang","year":"2019","journal-title":"BioMed Research International"},{"key":"10.7717\/peerj.20710\/ref-49","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.18632\/aging.204953","article-title":"The alleviating effect and mechanism of GLP-1 on ulcerative colitis","volume":"15","author":"Wang","year":"2023","journal-title":"Aging"},{"key":"10.7717\/peerj.20710\/ref-50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.7717\/peerj.20710\/ref-51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metabolism"},{"key":"10.7717\/peerj.20710\/ref-52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/dia.2010.0048","article-title":"Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus","volume":"13","author":"Wu","year":"2011","journal-title":"Diabetes Technology & Therapeutics"},{"key":"10.7717\/peerj.20710\/ref-53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12933-022-01634-1","article-title":"Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus","volume":"21","author":"Xie","year":"2022","journal-title":"Cardiovascular Diabetology"},{"key":"10.7717\/peerj.20710\/ref-54","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with Type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.7717\/peerj.20710\/ref-55","doi-asserted-by":"publisher","first-page":"e8652","DOI":"10.1590\/1414-431x20198652","article-title":"Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with csii: a pilot study","volume":"53","author":"Yao","year":"2020","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.7717\/peerj.20710\/ref-56","doi-asserted-by":"publisher","first-page":"N.PAG-N.PAG","DOI":"10.1186\/s13098-018-0392-8","article-title":"Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes","volume":"10","author":"Zhang","year":"2018","journal-title":"Diabetology & Metabolic Syndrome"},{"key":"10.7717\/peerj.20710\/ref-57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12933-020-01014-7","article-title":"Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Cardiovascular Diabetology"},{"key":"10.7717\/peerj.20710\/ref-58","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jbiomech.2013.01.010","article-title":"Morpho-mechanical intestinal remodeling in type 2 diabetic GK rats\u2014is it related to advanced glycation end product formation?","volume":"46","author":"Zhao","year":"2013","journal-title":"Journal of Biomechanics"},{"key":"10.7717\/peerj.20710\/ref-59","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.7717\/peerj.20710\/ref-60","doi-asserted-by":"publisher","first-page":"107282","DOI":"10.1016\/j.phrs.2024.107282","article-title":"Activation and modulation of the AGEs-RAGE axis: implications for inflammatory pathologies and therapeutic interventions\u2014a review","volume":"206","author":"Zhou","year":"2024","journal-title":"Pharmacological Research"},{"key":"10.7717\/peerj.20710\/ref-61","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/diagnostics11081431","article-title":"Effect of liraglutide on vascular inflammation evaluated by [64Cu]DOTATATE","volume":"11","author":"Zobel","year":"2021","journal-title":"Diagnostics"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20710.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20710.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20710.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:38:54Z","timestamp":1770107934000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":61,"alternative-id":["10.7717\/peerj.20710"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20710","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"e20710"}}